Friedberg noted that chemotherapy combined with an antibody remains a recommended treatment for patients with advanced-stage ...

Cure rate of 42% estimated in cure modeling; highest rate seen for patients with low Follicular Lymphoma International Prognostic Index scores.

Clinical-stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response ...

About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly ...

A new statistical analysis of patients with follicular lymphoma, made possible by 15 years of follow-up data from a SWOG and ...

Follicular lymphoma has long been considered incurable, but a study led by Wilmot Cancer Institute director Dr. Jonathan ...

Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all ...

Twenty years. That's how long Robert Oman has been cancer-free, thanks to a clinical trial offered at the University of ...

BeOne Medicines AG (NASDAQ:ONC) is among the 12 best stocks to buy and hold for the next 2 years. On February 26, BeOne ...

NICE recommends epcoritamab for relapsed follicular lymphoma, offering a new option after multiple lines of therapy.

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...